Skip to main content
OpenTrials
Completed

NCT Number: NCT07421180

Maternal Serum Adropin in Placenta Accreta Spectrum

Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion.

Methods:

This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Placenta Accreta Spectrum Female Urogenital Diseases and Pregnancy Complications Obstetric Labor Complications Placenta Accreta Placenta Diseases Placenta Previa Pregnancy Complications Urogenital Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

University of Heath and Science Adana City Hospital

Adana, Yuregir, 01100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women aged 18-45 years in the reproductive period
  • Singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS

Exclusion criteria

  • Uterine anomalies,
  • Chronic systemic diseases,
  • Multiple pregnancies,
  • Obstetric complications such as preterm premature rupture of membranes, threatened preterm labor, fetuses followed for intrauterine growth restriction, and placental abruption.

Treatment and study plan

Primary outcomes

  1. Blood serum Adropin levels

    Time frame: From 15.04.2024 to 01.04.2025

    The aim of the present study was to evaluate maternal serum adropin levels in pregnancies complicated by placenta previa and placenta accreta spectrum and compare to healthy controls.

Sponsors and collaborators

Lead sponsor

Adana City Training and Research Hospital

Other

Registry information

Official study title

Maternal Serum Adropin as a Potential Biomarker for Placenta Accreta Spectrum

Acronym: Adropin

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Feb 19, 2026
Registry last updated
Feb 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.